On Friday, Voyager Therapeutics Inc (NASDAQ: VYGR) opened lower -8.33% from the last session, before settling in for the closing price of $3.60. Price fluctuations for VYGR have ranged from $2.64 to $9.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -5.18%. Company’s average yearly earnings per share was noted -75.31% at the time writing. With a float of $45.00 million, this company’s outstanding shares have now reached $55.21 million.
Let’s determine the extent of company efficiency that accounts for 172 employees. In terms of profitability, gross margin is 48.55%, operating margin of -152.03%, and the pretax margin is -125.46%.
Voyager Therapeutics Inc (VYGR) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Voyager Therapeutics Inc is 18.69%, while institutional ownership is 62.86%. The most recent insider transaction that took place on Apr 02 ’25, was worth 34,595. In this transaction Chief Medical Officer of this company sold 10,086 shares at a rate of $3.43, taking the stock ownership to the 157,914 shares. Before that another transaction happened on Apr 02 ’25, when Company’s President and CEO sold 10,885 for $3.43, making the entire transaction worth $37,336. This insider now owns 430,931 shares in total.
Voyager Therapeutics Inc (VYGR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -75.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.46% during the next five years compared to 1.48% growth over the previous five years of trading.
Voyager Therapeutics Inc (NASDAQ: VYGR) Trading Performance Indicators
Check out the current performance indicators for Voyager Therapeutics Inc (VYGR). In the past quarter, the stock posted a quick ratio of 6.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.46, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -1.67 in one year’s time.
Technical Analysis of Voyager Therapeutics Inc (VYGR)
Looking closely at Voyager Therapeutics Inc (NASDAQ: VYGR), its last 5-days average volume was 0.82 million, which is a jump from its year-to-date volume of 0.44 million. As of the previous 9 days, the stock’s Stochastic %D was 54.23%. Additionally, its Average True Range was 0.27.
During the past 100 days, Voyager Therapeutics Inc’s (VYGR) raw stochastic average was set at 19.76%, which indicates a significant decrease from 60.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.89% in the past 14 days, which was higher than the 73.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.26, while its 200-day Moving Average is $5.06. However, in the short run, Voyager Therapeutics Inc’s stock first resistance to watch stands at $3.45. Second resistance stands at $3.61. The third major resistance level sits at $3.72. If the price goes on to break the first support level at $3.19, it is likely to go to the next support level at $3.08. Should the price break the second support level, the third support level stands at $2.92.
Voyager Therapeutics Inc (NASDAQ: VYGR) Key Stats
There are currently 55,336K shares outstanding in the company with a market cap of 182.61 million. Presently, the company’s annual sales total 80,000 K according to its annual income of -65,000 K. Last quarter, the company’s sales amounted to 6,470 K and its income totaled -31,020 K.
